EcoDrugPlus

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOKIG00005020644
Gene Symbol: PSMA8
3 Cross references
166 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOKIG00005010511
Gene Symbol: PSMA8
1 Cross references
167 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSOKIG00005009134
Gene Symbol: PSMB1
1 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSOKIG00005046699
Gene Symbol: PSMB10
1 Cross references
164 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSOKIG00005012152
Gene Symbol: PSMB11B
1 Cross references
159 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSOKIG00005003016
Gene Symbol: PSMB3
3 Cross references
254 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSOKIG00005035450
Gene Symbol: PSMB4
1 Cross references
208 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOKIG00005050784
Gene Symbol: PSMB5
1 Cross references
146 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOKIG00005039910
Gene Symbol: PSMB5
1 Cross references
190 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOKIG00005012178
Gene Symbol: PSMB5
3 Cross references
158 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOKIG00005002023
Gene Symbol: PSMB5
3 Cross references
158 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSOKIG00005031225
Gene Symbol: PSMB6
1 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).